PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18538114-13 2008 CONCLUSIONS: These results indicate that MMF could be an alternative therapy for anti-MPO renal vasculitis associated with cyclophosphamide or azathioprine-related toxicity. Cyclophosphamide 123-139 myeloperoxidase Homo sapiens 86-89 24357324-3 2014 However, after cyclophosphamide was replaced with intravenous tocilizumab, the aortitis was improved, and the prednisolone dose was successfully tapered to 4 mg/day without elevation in C-reactive protein and myeloperoxidase ANCA (MPO-ANCA) levels. Cyclophosphamide 15-31 myeloperoxidase Homo sapiens 231-234 24608395-11 2014 CONCLUSION: Corticosteroids and cyclophosphamide are effective in the treatment of MPO-ANCA associated glomerulonephritis in MCTD. Cyclophosphamide 32-48 myeloperoxidase Homo sapiens 83-86 23352254-2 2013 METHODS: We report a case of anti-GBM antibody disease with both anti-GBM antibodies and anti-myeloperoxidase (MPO) specific p-ANCA, who developed thrombotic thrombocytopenic purpura (TTP) on high dose prednisone, plasmapheresis, and cyclophosphamide therapy. Cyclophosphamide 234-250 myeloperoxidase Homo sapiens 89-109 23352254-2 2013 METHODS: We report a case of anti-GBM antibody disease with both anti-GBM antibodies and anti-myeloperoxidase (MPO) specific p-ANCA, who developed thrombotic thrombocytopenic purpura (TTP) on high dose prednisone, plasmapheresis, and cyclophosphamide therapy. Cyclophosphamide 234-250 myeloperoxidase Homo sapiens 111-114 22307556-0 2012 Improvement in health-related quality of life in MPO-ANCA-associated vasculitis patients treated with cyclophosphamide plus prednisolone: an analysis of 18 months of follow-up data from the JMAAV study. Cyclophosphamide 102-118 myeloperoxidase Homo sapiens 49-52 22307556-1 2012 OBJECTIVES: To examine the improvement in health-related quality of life (HRQOL) in association with disease activity in myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis patients treated with cyclophosphamide plus prednisolone. Cyclophosphamide 230-246 myeloperoxidase Homo sapiens 121-136 22307556-1 2012 OBJECTIVES: To examine the improvement in health-related quality of life (HRQOL) in association with disease activity in myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis patients treated with cyclophosphamide plus prednisolone. Cyclophosphamide 230-246 myeloperoxidase Homo sapiens 138-141 21738257-0 2011 Hepatotoxicity following cyclophosphamide treatment in a patient with MPO-ANCA vasculitis. Cyclophosphamide 25-41 myeloperoxidase Homo sapiens 70-73 23517575-10 2013 cyclophosphamide pulses monthly for 6 doses, followed by mycophenolate mofetil that resulted in normal lung function tests, hemoglobin concentration, and anti-MPO level within four subsequent weeks. Cyclophosphamide 0-16 myeloperoxidase Homo sapiens 159-162 19752340-8 2009 CONCLUSION: These results, observed in two independent study populations, indicate that high-activity MPO genotypes are associated with better survival among women receiving cyclophosphamide-containing therapy, particularly when followed by tamoxifen therapy. Cyclophosphamide 174-190 myeloperoxidase Homo sapiens 102-105 10536484-2 1999 We described here a 15-year-old boy with positive anti-neutrophil cytoplasmic antibody (MPO-ANCA) and severe mPAN, who was effectively treated with intravenous methylprednisolone pulse therapy followed by monthly cyclophosphamide pulses for 1 year. Cyclophosphamide 213-229 myeloperoxidase Homo sapiens 88-91 10793033-5 2000 Therapy with oral prednisone and cyclophosphamide led to resolution of pulmonary hemorrhage and negativity of MPO-ANCA. Cyclophosphamide 33-49 myeloperoxidase Homo sapiens 110-113 14598658-11 2003 Methylprednisolone pulse therapy followed by intravenous cyclophosphamide pulse therapy improved his clinical conditions such as pyrexia, cough, myalgia, episcleritis and respiratory symptoms with decreased titer of serum MPO-ANCA. Cyclophosphamide 57-73 myeloperoxidase Homo sapiens 222-225 12460408-1 2002 To minimize the adverse effects of high-dose administration of steroids and cyclophosphamide in patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA), granulocytapheresis (GCAP) or leukocytapheresis (LCAP) was performed to reduce inflammation. Cyclophosphamide 76-92 myeloperoxidase Homo sapiens 110-125 12460408-1 2002 To minimize the adverse effects of high-dose administration of steroids and cyclophosphamide in patients with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA), granulocytapheresis (GCAP) or leukocytapheresis (LCAP) was performed to reduce inflammation. Cyclophosphamide 76-92 myeloperoxidase Homo sapiens 127-130 12324935-4 2002 Treatment with steroid and cyclophosphamide resulted in significant improvement in renal function and normalization of MPO-ANCA level. Cyclophosphamide 27-43 myeloperoxidase Homo sapiens 119-122 8940829-8 1996 Under the diagnosis of MPO-ANCA-associated CreGN, cocktail therapy consisting of prednisolone, cyclophosphamide, dilazep hydrochloride and warfarin was started. Cyclophosphamide 95-111 myeloperoxidase Homo sapiens 23-26 33505756-12 2021 After treatment with methylprednisolone and intravenous cyclophosphamide pulse therapies, renal function improved and MPO-ANCA levels decreased. Cyclophosphamide 56-72 myeloperoxidase Homo sapiens 118-121 8731685-6 1996 Treatment with prednisone and cyclophosphamide was started with a good clinical response, stabilization of renal insufficiency and disappearance of P-ANCA (MPO). Cyclophosphamide 30-46 myeloperoxidase Homo sapiens 156-159 27333332-8 2016 Patients with MPO-ANCA-positive GPA frequently had limited disease without severe organ involvement, had a high prevalence of subglottic stenosis, and had less need for aggressive immunosuppressive therapy (cyclophosphamide/rituximab). Cyclophosphamide 207-223 myeloperoxidase Homo sapiens 14-17